Tumor necrosis factor alpha–Tumor necrosis factor receptor 1 interaction (TNFα–TNFR1)

The interaction between Tumor Necrosis Factor alpha (TNFα) and Tumor Necrosis Factor Receptor 1 (TNFR1) is a fundamental signaling event in the human immune system, governing responses to infection and tissue injury. TNFα, a potent pro-inflammatory cytokine, binds to the ubiquitously expressed TNFR1 to initiate intracellular pathways such as NF-κB and MAPK, which promote the expression of inflammatory genes and cell survival. However, under specific conditions, this interaction also triggers programmed cell death through apoptosis or necroptosis via the recruitment of death-domain-containing proteins like TRADD and FADD. Chronic overactivation of the TNFα–TNFR1 axis is a hallmark of various autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. Therapeutic intervention has traditionally relied on biologics like infliximab and adalimumab, which neutralize TNFα to prevent its binding to both TNFR1 and TNFR2. More recent drug development efforts focus on selective TNFR1 antagonists to block pro-inflammatory signaling while sparing the regenerative and immunomodulatory functions of TNFR2. This selectivity is hypothesized to reduce common side effects of broad TNF inhibition, such as increased susceptibility to infections and demyelinating disorders.

Other names

TNF-TNFR1 complexTNF-TNFRSF1A interactionTNF-CD120a interactionTNF-p55 interactionTumor necrosis factor-Tumor necrosis factor receptor superfamily member 1A interaction

Inhibition of ligand-receptor binding through neutralization of TNFα or selective antagonism of the TNFR1 receptor to block pro-inflammatory and apoptotic signaling cascades.